title: Profiling of substrate specificities of 3C-like proteases from group 1, 2a, 2b, and 3 coronaviruses.
abstract: BACKGROUND
  Coronaviruses (CoVs) can be classified into alphacoronavirus (group 1), betacoronavirus (group 2), and gammacoronavirus (group 3) based on diversity of the protein sequences. Their 3C-like protease (3CL(pro)), which catalyzes the proteolytic processing of the polyproteins for viral replication, is a potential target for anti-coronaviral infection.
  
  
  RESULTS
  Here, we profiled the substrate specificities of 3CL(pro) from human CoV NL63 (group 1), human CoV OC43 (group 2a), severe acute respiratory syndrome coronavirus (SARS-CoV) (group 2b) and infectious bronchitis virus (IBV) (group 3), by measuring their activity against a substrate library of 19 × 8 of variants with single substitutions at P5 to P3' positions. The results were correlated with structural properties like side chain volume, hydrophobicity, and secondary structure propensities of substituting residues. All 3CL(pro) prefer Gln at P1 position, Leu at P2 position, basic residues at P3 position, small hydrophobic residues at P4 position, and small residues at P1' and P2' positions. Despite 3CL(pro) from different groups of CoVs share many similarities in substrate specificities, differences in substrate specificities were observed at P4 positions, with IBV 3CL(pro) prefers P4-Pro and SARS-CoV 3CL(pro) prefers P4-Val. By combining the most favorable residues at P3 to P5 positions, we identified super-active substrate sequences 'VARLQ↓SGF' that can be cleaved efficiently by all 3CL(pro) with relative activity of 1.7 to 3.2, and 'VPRLQ↓SGF' that can be cleaved specifically by IBV 3CL(pro) with relative activity of 4.3.
  
  
  CONCLUSIONS
  The comprehensive substrate specificities of 3CL(pro) from each of the group 1, 2a, 2b, and 3 CoVs have been profiled in this study, which may provide insights into a rational design of broad-spectrum peptidomimetic inhibitors targeting the proteases.
authors.affiliation: School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China.
authors.forename: Chi-Pang
authors.initials: CP
authors.lastname: Chuck
authors.forename: Hak-Fun
authors.initials: HF
authors.lastname: Chow
authors.forename: David Chi-Cheong
authors.initials: DC
authors.lastname: Wan
authors.forename: Kam-Bo
authors.initials: KB
authors.lastname: Wong
mesh_terms: D003001:Cloning, Molecular; D017934:Coronavirus / Q000145:classification / Q000201:enzymology*; D008958:Models, Molecular; D008969:Molecular Sequence Data; D010447:Peptide Hydrolases / Q000235:genetics / Q000378:metabolism*; D013379:Substrate Specificity
chemical_list: D010447:Peptide Hydrolases
references.citation: J Mol Biol. 2003 Aug 29;331(5):991-1004
references.pmid: 12927536
references.citation: J Exp Med. 1949 Sep;90(3):181-210
references.pmid: 18137294
references.citation: J Clin Microbiol. 2010 Aug;48(8):2940-7
references.pmid: 20554810
references.citation: Microbiol Rev. 1992 Mar;56(1):61-79
references.pmid: 1579113
references.citation: Lancet. 1966 Jan 8;1(7428):76-7
references.pmid: 4158999
references.citation: Biophys Chem. 2008 May;134(3):185-99
references.pmid: 18342425
references.citation: Vet Res. 2007 Mar-Apr;38(2):281-97
references.pmid: 17296157
references.citation: J Virol. 2008 Sep;82(17):8647-55
references.pmid: 18562531
references.citation: Lancet. 2003 Jul 26;362(9380):263-70
references.pmid: 12892955
references.citation: J Gen Virol. 2002 Mar;83(Pt 3):595-599
references.pmid: 11842254
references.citation: Adv Enzymol Relat Areas Mol Biol. 1978;47:45-148
references.pmid: 364941
references.citation: Antiviral Res. 2011 Nov;92(2):204-12
references.pmid: 21854807
references.citation: J Gen Virol. 2006 Jun;87(Pt 6):1403-1421
references.pmid: 16690906
references.citation: Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7
references.pmid: 15226499
references.citation: J Mol Biol. 1982 May 5;157(1):105-32
references.pmid: 7108955
references.citation: J Virol. 2004 Aug;78(15):7863-6
references.pmid: 15254158
references.citation: FEBS Lett. 2004 Sep 10;574(1-3):131-7
references.pmid: 15358553
references.citation: Antiviral Res. 2005 Jul;67(1):18-23
references.pmid: 15885816
references.citation: Biochem Biophys Res Commun. 2005 Apr 15;329(3):934-40
references.pmid: 15752746
references.citation: Biochemistry. 2007 Jul 31;46(30):8744-52
references.pmid: 17605471
references.citation: J Med Virol. 2009 Sep;81(9):1597-604
references.pmid: 19626607
references.citation: Science. 2003 Jun 13;300(5626):1763-7
references.pmid: 12746549
references.citation: Nat Rev Genet. 2008 Apr;9(4):267-76
references.pmid: 18319742
references.citation: J Am Vet Med Assoc. 1946 Apr;108:257-9
references.pmid: 21020443
references.citation: J Mol Evol. 2002 Feb;54(2):156-65
references.pmid: 11821909
references.citation: PLoS One. 2010 Oct 06;5(10):e13197
references.pmid: 20949131
references.citation: Nat Med. 2004 Apr;10(4):368-73
references.pmid: 15034574
references.citation: J Virol. 2005 Jan;79(2):884-95
references.pmid: 15613317
references.citation: Exp Biol Med (Maywood). 2009 Oct;234(10):1117-27
references.pmid: 19546349
references.citation: PLoS Biol. 2005 Oct;3(10):e324
references.pmid: 16128623
references.citation: Rev Sci Tech. 2000 Aug;19(2):493-508
references.pmid: 10935276
references.citation: J Virol. 2005 Feb;79(4):2001-9
references.pmid: 15681402
references.citation: J Virol. 2008 Mar;82(5):2515-27
references.pmid: 18094151
references.citation: Proc Soc Exp Biol Med. 1966 Jan;121(1):190-3
references.pmid: 4285768
references.citation: Proc Annu Meet U S Anim Health Assoc. 1974;(78):359-66
references.pmid: 4377955
references.citation: J Virol. 2005 Jun;79(11):7095-103
references.pmid: 15890949
references.citation: Lancet. 2003 Apr 19;361(9366):1319-25
references.pmid: 12711465